IQV Stock Analysis — IQVIA Holdings Inc.
Sector: Healthcare Data & Services
AI Verdict
IQVIA trades cheap for the explosive earnings growth analysts expect, but the overheated RSI warns that buyers risk a sharp pullback if momentum stalls, even with its entrenched data advantage.
Competitive Moat
IQVIA runs one of the world’s largest proprietary healthcare data networks, aggregating clinical, prescription, and patient data that pharmaceutical companies rely on for drug development and commercialization. Its scale and exclusive data partnerships create high switching costs and a defensible position in clinical trial analytics.
Summary
IQVIA is on watch as its forward P/E drops to 16.2x while analysts expect a massive 58.8% jump in earnings next year.
Where It Stands
Shares are up 27.67% over the past year, the RSI is extremely overbought at 87.5, and the stock trades at 16.2x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 87.5 — Overbought
- Trailing P/E: 25.8x
- Forward P/E: 16.2x
- PEG Ratio: 0.44
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $34.7B
- 1-Year Return: 27.67%
- 52-Week High: $247.05
- 52-Week Low: $154.50
Analyst Consensus
22 Buy · 7 Hold · 0 Sell (29 analysts)
Bull Case
You’re paying just 16.2x next year’s earnings for a business expected to grow EPS by 58.8%, which is cheap for this level of growth if its data moat holds.
Bear Case
The RSI at 87.5 signals extreme overbought conditions, so a pullback to neutral RSI (65) could mean a 15–20% correction even if fundamentals stay intact.
Catalyst to Watch
Watch for upcoming clinical trial wins or new data partnerships, as these directly impact the credibility of the 58.8% EPS growth forecast.